Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 8/2016

01-08-2016 | Original Article

Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study

Authors: I. Mahé, H. Puget, J. C. Buzzi, M. Lamuraglia, J. Chidiac, A. Strukov, Hélène Helfer, A. Perozziello

Published in: Supportive Care in Cancer | Issue 8/2016

Login to get access

Abstract

Purpose

French 2008 treatment guidelines recommend low-molecular-weight heparins (LMWH) for the treatment of cancer-associated thrombosis (CAT) with treatment duration of at least 3 months and up to 6 months and beyond if cancer remains active. Our aim was to assess adherence to guidelines in hospital clinical practice.

Methods

The French hospital database (PMSI) was used to identify patients with CAT admitted to three hospitals of the Paris region to be included in a retrospective cohort study. Adherence to guidelines was assessed in patients included from different treatment periods following the venous thromboembolism (VTE) episode i.e. first 10 days (T1), day 10 to 3 months (T2), months 3 to 6 (T3) and beyond 6 months (T4) when applicable.

Results

A total of 240 patients with CAT were included from January 2012 to December 2012 of whom 204 were analyzable. Treatment was adherent to guidelines in 55, 31 and 34 % of patients in T1, T2 and T3 treatment periods, respectively, while overall treatment adherence was found in 52 % of patients. Adherence rates were the highest among patients with pulmonary embolism (PE, 60.5 %), catheter-related thrombosis (62.5 %), class III/IV extended cancer (58.0 %) and metastatic malignancy (60.3 %) while only 40 % with deep vein thrombosis (DVT) received a treatment consistent with guidelines.

Conclusion

Adherence to guidelines appears insufficient since only half of patients received an appropriate treatment. Adherence dropped significantly across treatment periods T2 and T3. VTE diagnosis and cancer characteristics influenced the anticoagulant prescription. Management of patients with CAT requires further education and information of health care professionals.
Literature
1.
Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464CrossRefPubMed
2.
Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk Analysis Using Medicare Claims Data Medicine (Baltimore) 78:285–291
3.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632–634CrossRefPubMed
4.
Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D’Angelo A, Pengo V, Moia M, Coccheri S (2000) A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 84:805–810PubMed
5.
Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci ML, Levesque H, Renaudin JM, Farge D (2009) Working group of the SOR, French National Federation of Cancer C. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 20:1459–1471CrossRef
6.
Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, Cajfinger F, Desmurs-Clavel H, Elias A, Grange C, Hocini H, Legal G, Mahe I, Quere I, Levesque H, Debourdeau P (2010) 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol 73:31–46CrossRefPubMed
7.
Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, et al. (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 11:56–70CrossRefPubMed
8.
Delate T, Witt DM, Ritzwoller D, Weeks JC, Kushi L, Hornbrook MC, Aiello Bowles EJ, Schrag D (2012) Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist 17:419–427CrossRefPubMedPubMedCentral
9.
Spirk D, Ugi J, Korte W, Husmann M, Hayoz D, Baldi T, Frauchiger B, Banyai M, Aujesky D, Baumgartner I, Kucher N (2011) Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II. Thromb Haemost 105:962–967CrossRefPubMed
10.
Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A, Lopez-Jimenez L, Garcia-Bragado F, Quintavalla R, Monreal M, Investigators R (2010) Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 125(Suppl 2):S58–S61CrossRefPubMed
11.
Belhadj Chaidi R, Thollot C, Ferru A, Roblot P, Landron C (2013) Adherence to guidelines for the treatment of venous thromboembolism in cancer patients: a retrospective analysis of 145 cases. J Mal Vasc 38:185–192CrossRefPubMed
12.
Sevestre MA, Belizna C, Durant C, Bosson JL, Vedrine L, Cajfinger F, Debourdeau P, Farge D (2014) Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study. J Mal Vasc 39:161–168CrossRefPubMed
13.
Farge D, Gorin NC, Debourdeau P, Lamblin A, Cajfinger F (2014) Long-term use of low-molecular-weight heparin (LMWH) for cancer (associated venous thromboembolism (VTE): adherence to recommendations in clinical practice based on tropique, a prospective observational study. Blood Coagul Fibrinolysis: Int J Haemost Thromb 124(21):1545
14.
AFSOS 2013 Prise en charge de la maladie thromboembolique veineuse en cancérologie. Référentiels de l’Association Francophone pour les Soins Oncologiques de Support wwwafsosorg
15.
Sousou T, Khorana A (2009) Identifying cancer patients at risk for venous thromboembolism. Hamostaseologie 29:121–124PubMed
16.
Cimminiello C, Anderson FA Jr (2012) Physician and patient perceptions of the route of administration of venous thromboembolism prophylaxis: results from an international survey. Thromb Res 129:139–145CrossRefPubMed
17.
Seaman S, Nelson A, Noble S (2014) Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence 8:453–461PubMedPubMedCentral
18.
Akl EA, Kahale L, Barba M, Neumann I, Labedi N, Terrenato I, Sperati F, Muti P, Schunemann H (2014) Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 7:CD006650PubMed
19.
Heit JA (2005) Cancer and venous thromboembolism: scope of the problem. Cancer Control: J Moffitt Cancer Center 12(Suppl 1):5–10
Metadata
Title
Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study
Authors
I. Mahé
H. Puget
J. C. Buzzi
M. Lamuraglia
J. Chidiac
A. Strukov
Hélène Helfer
A. Perozziello
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 8/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3164-8

Other articles of this Issue 8/2016

Supportive Care in Cancer 8/2016 Go to the issue

Original Article

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

Letter to the editor

Comment on “Safety and tolerability of Kinesio® Taping in patients with arm lymphedema: medical device clinical study”

Letter to the editor

Lung cancer stigma and patient-provider communication: a complex association

Original Article

Implementation of a mobile inpatient quality of life (QoL) assessment for oncology nursing

Original Article

Use of the Needs Evaluation Questionnaire with cancer outpatients

Erratum

Erratum to: Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits